whatshot

HRTX   $1.55  -3.73% Market Closed After Close 1.55 0.0

Heron Therapeutics Inc
show_chart Advanced Chart of HRTX
Last Events:

2023-08-06 Trend pattern changed from нисходящий треугольник to канал.

2023-08-06 Signal in Stochastic changed from bearish to bullish. The stochastic indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: main and signal line crossing.

2023-08-05 Signal in MACD changed from bullish weakening to bullish recovery. Oscillator MACD is in the positive territory it's higher than the signal line and grows. These factors mean that positive mood prevails. Last signal: signal line crossed the middle level.

2023-08-05 Signal in RSI changed from bullish weakening to bullish recovery. RSI indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-04 Signal in MACD changed from bullish to bullish weakening. Oscillator MACD is in the positive territory it's higher than the signal line and falls. These factors mean that the growing trend persists, but the growth rate is declining. Last signal: signal line crossed the middle level.

2023-08-03 Signal in Stochastic changed from bullish weakening to bearish. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: signal line crossed the middle level.

2023-08-03 Signal in RSI changed from bullish recovery to bullish weakening. RSI indicator is in the upper part of the neutral territory and it heading south. These factors indicate that the downside trend is forming. Last signal: entrance to the overbought zone.

2023-08-03 Trend changed from linear down to down and flat.

Current temperature: 0.00
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 3
Target Price Mean 6.00
Mean unverified/preliminary 6.00 / 6.00
Target Price Low / High 4.00 / 9.00
Median / STD DEV 5.00 / 2.65
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total None None ActivelyBuy
rsi ActivelyBuy ActivelyBuy None
macd None None None
stoch None None None
ma20 ActivelyBuy None ActivelyBuy
ma50 None None None
ma100 None None None
Candlestick PatternDec. 10, 2024 Long Legged - consists of a Doji with very long upper and lower shadows. Indicates strong forces balanced in opposition.
ISIN US4277461020
ceo Mr. Craig Alexander Collard
Website https://www.herontx.com
Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.